Sanofi New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent dupilumab improved moderatetosevere asthma

Press Release Source Sanofi EURONEXT SAN NYSE SNY New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent dupilumab improved moderatetosevere asthma Res…
Read the full story: Bioportfolio Biomarker News